Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Optimal pupil size for asymmetrical multifocal intraocular lens (MFIOL)

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Multifocal II

Session Date/Time: Tuesday 13/09/2016 | 08:00-10:30

Paper Time: 10:04

Venue: Auditorium C6

First Author: : E.Pazo UK

Co Author(s): :    J. Moore   R. McNelly   T. Moore   O. Richoz   A. Nesbit        

Abstract Details

Purpose:

To assess how varying area of ‘distance-add’ exposed within the photopic and mesopic pupil, impacts the visual outcome, when implanting asymmetrical MFIOL.

Setting:

Cathedral Eye Clinic, Belfast, Northern Ireland, UK.

Methods:

Three-hundred consecutive patients (164 females and 136 males) implanted with SBL-3 (Lenstec) or MF-30 (Lentis) rotationally asymmetric MFIOL were followed for 3 years. Pupil diameter was measured using OPD scan (Nidek) and intraindividual comparisons were made between preoperative and postoperative pupil diameter and quality of vision (QOV) questionnaire scores assessed at 1, 2 and 3 years postoperatively.

Results:

The mean mesopic and photopic pupil diameter decreased significantly from preoperative to 3 year postoperative (5.8 ± 1.6 mm to 3.7 ± 1.2 mm and 4.3 ± 0.3 to 3.2 ± 0.5 mm respectively) assessment. There was a significant correlation between the QOV questionnaire score and pupil diameter, confirming that the surface area IOL exposed within the pupil impacts vision. The average pupil diameter for optimal QOV was 3.5 ± 0.4 mm. In general QOV score were better with larger preoperative pupils.

Conclusions:

A quantitative method of pupil assessment can be used to identify preoperative eyes and their QOV over time; this methodology can be used to improvement current screening strategies in rotationally asymmetrical MFIOL patients after validation.

Financial Disclosure:

NONE

Back to previous